Lastly, elevated or aberrant activation of mTOR has been identified in several cell lines and patient samples of DLBCL and MCL; thus, its targeting is a therapeutic approach alone or in combination [113]. The gene discussed is MTOR; the disease is diffuse large B-cell lymphoma.